Abstract:Inflammation, an important biological protective response to tissue damage or microbial invasion, is considered to be an alarming signal for the progress of varied biological complications. Based on the previous reports in the literature that proved the noticeable efficacy of pyrazole and thiazole scaffold as well as nitrogen heterocyclic based compounds against acute and chronic inflammatory disease, a new set of novel D-ring substituted steroidal 4,5-dihydropyrazole thiazole derivatives were synthesized and evaluated their anti-inflammatory activities in vitro. Preliminary structure-activity relationship (SAR) analysis was conducted by their inhibitory activities against nitric oxide (NO) release in lipopolysaccharide (LPS)-induced RAW 264.7 cells, and the optimal compound 12b [3β-hydroxy-pregn-5-en-17β-yl-5'- (o- chlorophenyl)- 1'-(4''- phenyl -[1'', 3'']- thiazol-2''- yl) - 4',5'-dihydro - 1'H-pyrazol - 3'- yl] exhibited more potent anti-inflammatory activity than the positive control treatment methylprednisolone (MPS), with an IC50 value of 2.59 μM on NO production and low cytotoxicity against RAW 264.7 cells. In further mechanism study, our results showed that compound 12b significantly suppressed the production of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and inhibited the expressions of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) through blocking NF-κB p65 nuclear translocation and phosphorylation of IκBα. Compound 12b also attenuated LPS-induced activation of c-Jun amino-terminal kinase (JNK) and p38 phosphorylation in RAW 264.7 cells. Molecular docking study revealed the strong binding affinity of compound 12b to the active site of the COX-2 proteins, which confirmed that compound 12b acted as an anti-inflammatory mediator. These results indicate that steroidal derivatives bearing 4,5-dihydropyrazole thiazole structure might be considered for further research and scaffold optimization in designing anti-inflammatory drugs and compound 12b might be a promising therapeutic anti-inflammatory drug candidate.

7B, a Novel Naphthalimide Derivative, Exhibited Anti-Inflammatory Effects Via Targeted-Inhibiting TAK1 Following Down-Regulation of ERK1/2- and P38 MAPK-mediated Activation of NF-κB in LPS-stimulated RAW264.7 Macrophages

In Vitro and in Vivo Anti-Inflammatory Effects of Polyphyllin VII Through Downregulating MAPK and NF-κB Pathways

Synthesis Compound XCR-7a Ameliorates LPS-induced Inflammatory Response by Inhibiting the Phosphorylation of C-Fos

Regulation of inflammatory cytokines in lipopolysaccharide-stimulated RAW 264.7 murine macrophage by 7-O-methyl-naringenin.

Anti-Inflammatory Effects of 6-Methylcoumarin in LPS-Stimulated RAW 264.7 Macrophages via Regulation of MAPK and NF-κB Signaling Pathways

7B, a Novel Amonafide Analog, Inhibited Proliferation and Phorbol 12-Myristate 13-Acetate/phytohemagglutinin-induced Inflammatory Responses of Jurkat T Cells Via P73-Dependent Pathway and Decrease of Nuclear Factor-Κb DNA-binding, Respectively.

Chlojaponilactone B Attenuates Lipopolysaccharide-Induced Inflammatory Responses by Suppressing TLR4-Mediated ROS Generation and NF-κB Signaling Pathway

Design and synthesis of adamantyl-substituted flavonoid derivatives as anti-inflammatory Nur77 modulators: Compound B7 targets Nur77 and improves LPS-induced inflammation in vitro and in vivo

The P38 MAPK Inhibitor JLU1124 Inhibits the Inflammatory Response Induced by Lipopolysaccharide Through the MAPK-NF-κB Pathway in RAW264.7 Macrophages.

A Novel Chromone Derivative With Anti-Inflammatory Property Via Inhibition Of Ros-Dependent Activation Of Traf6-Ask1-P38 Pathway

Design, Synthesis, and Biological Activity of Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives as Anti-Inflammatory Agents

Design, synthesis and molecular docking of novel D-ring substituted steroidal 4,5-dihydropyrazole thiazole derivatives that act as iNOS/COX-2 inhibitors with potent anti-inflammatory activity against LPS-induced RAW264.7 macrophage cells

Inhibitory effect of 5-Pyridin-2-ylmethylene-6,7-dihydro-5H-benzo[b]thiophen-4-one (PT-2-318) on NF-kB and AP-1 activation in macrophages (CAM5P.235)

In vitro and in vivo biological evaluation of Lappaconitine derivatives as potential anti-inflammatory agents

Anti-Inflammatory Activity of 1,4-Naphthoquinones Blocking P2X7 Purinergic Receptors in RAW 264.7 Macrophage Cells

Nauclea Officinalis Inhibits Inflammation in LPS-mediated RAW 264.7 Macrophages by Suppressing the NF-κB Signaling Pathway.

Potential role of a series of lysine-/leucine-rich antimicrobial peptide in inhibiting lipopolysaccharide-induced inflammation.

Benzoylaconine Modulates LPS-Induced Responses Through Inhibition of Toll-Like Receptor-Mediated NF-κB and MAPK Signaling in RAW264.7 Cells

Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 9

Inflammation Regulation Via an Agonist and Antagonists of Α7 Nicotinic Acetylcholine Receptors in RAW264.7 Macrophages.

Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation